西米达衍生物在乳腺癌中:针对特定目标的治疗突破
S Mounika1, Hemalatha K1, Rohit Pal1
1Integrated Drug Discovery Centre, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru 560107, Karnataka, India.
Current topics in medicinal chemistry
|January 9, 2025
概括
与传统化疗相比,西米达衍生物显示出作为乳腺癌向治疗的有望性,提供更好的疗效和减少副作用. 本综述强调了这些新型抗癌药物的最新进展和正在进行的临床试验.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是妇女死亡的主要原因,化疗面临毒性和耐药性等挑战.
- 向治疗提供了一种更精确的癌症治疗方法,通过专注于特定的瘤标志物.
- 西米达衍生物正在成为开发新型抗乳腺癌药物的一类有前途的化合物.
研究的目的:
- 为提供近期 (2019-2024) 针对乳腺癌向治疗的本齐米达衍生物的突破提供概述.
- 为了阐明杂交的胺醇化合物,它们的生物点和抗癌活性.
- 收集有关正在进行的临床试验的信息,涉及在乳腺癌治疗中使用本齐米达支架.
主要方法:
- 2019-2024年科学出版物和临床试验数据库的文献综述.
- 分析本齐米达衍生物的结构-活性关系.
- 合成和评估新型本齐米达化合物的生物活性 (隐含).
主要成果:
- 西米达衍生物对各种癌症细胞类型具有显著的细胞毒性.
- 混合的本齐米达结构显示出多种生物标和抗乳腺癌活性.
- 目前,一些基于本齐米达的药物正在为乳腺癌进行临床试验.
结论:
- 西米达衍生物是开发乳腺癌强效和选择性向疗法的宝贵支架.
- 对结构-活性关系的进一步研究可以优化这些化合物的疗效.
- 目前正在进行的临床试验表明,基于本齐米达的治疗方法在抗击乳腺癌方面具有前景.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


